Drug intelligence / Profile preview

FFP104

Development stage: Phase 2
Lead developer: Fast Forward Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FFP104 is a humanized monoclonal antibody that acts as an antagonist of CD40, a member of the tumor necrosis factor receptor superfamily. It was developed by Fast Forward Pharmaceuticals for the treatment of autoimmune and inflammatory diseases, particularly Crohn’s disease and primary biliary cholangitis (previously called primary biliary cirrhosis). By inhibiting CD40 signaling, which plays a key role in immune activation and inflammation, FFP104 aims to modulate abnormal immune responses underlying these conditions. The drug is administered intravenously and has been evaluated in Phase I/II clinical trials for safety, tolerability, pharmacodynamics, and efficacy[2][3][4][5][6].

Other names: FFP 104FFP104FFP-104

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on FFP104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FFP104.

Explore the full profile